Medical Xpress

Study reveals combined use of Donepezil/Memantine increases probability of five-year survival in Alzheimer's patients

Alzheimer's disease is the world's most common neurodegenerative disease, affecting more than 50 million people globally. Alzheimer's disease is also among the most fatal, landing as one of the top ...
Nasdaq

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
ALZFORUM

Trial of Memantine/Donepezil Paves the Way for Combination Therapy

Combining memantine with an older, widely used AD drug further improves measures of cognition, global well-being, activities of daily living, and behavior in people with moderate to severe AD, ...
Yahoo

Pills for memory: The medications that define dementia care today

For decades, dementia, especially Alzheimer’s disease, was treated as untouchable. Families watched loved ones fade, doctors could offer only reassurance and coping strategies, and research seemed to ...
FiercePharma

donepezil and Forest Laboratories’ Namenda Lead All Other Therapies Approved for Alzheimer’s Disease by a Wide Margin in U

In the Treatment of Alzheimer’s Disease, Polypharmacy Increases Across Lines of Therapy, According to New Analysis from Decision Resources BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one ...
ALZFORUM

Memantine Claimed to Augment Donepezil's Effects

Forest Laboratories, Inc., reported last week that patients with moderate to severe Alzheimer's disease taking memantine and donepezil had significant improvement over patients on donepezil alone on ...
FiercePharma

Actavis and Adamas Announce FDA Approval of NamzaricTM, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride

- Indicated for Treatment of Moderate to Severe Alzheimer's Disease - DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS ...